The liquidation of HiberGene Diagnostics, an Irish medtech company that makes diagnostic tests for human infectious diseases, has been completed with the intellectual property of the business sold for €85,000. The liquidator of HiberGene has previously told investors that there will not be a dividend to any class of creditor of the company. This has been reaffirmed to creditors in the final report of the company’s liquidator, Colin Gaynor of Resolute Advisory.  Founded in 2009, HiberGene had raised almost €15 million from investors and secured over €1 million in government grants, according to its last balance sheet established at the…

Want to continue reading?

Join today with an Annual membership and unlock full access to The Currency and The Wall Street Journal for just €200 – two premium memberships, one subscription.

Subscribe

Cancel at any time.

Are you already a member? .